Humira(CF) pen 40 MG/0.4 MLS
Ended Awarded
- Contract number
- SPE2DR26FB4PD
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $32,036
Award facts
- Contract value 100% obligated
- $32,035.51 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
This delivery order, awarded November 13, 2025, by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, covers the supply of HUMIRA (Adalimumab) CF Pen 40 mg/0.4 mL doses with a ceiling value of $32,035.51. The contract is structured as a firm fixed-price delivery order with no set-aside designation, indicating competitive award status. Performance will be executed from the vendor's location in Conshohocken, Pennsylvania, with a completion deadline of November 14, 2025. This award is a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime vendor agreement valued through December 2026 that provides comprehensive pharmaceutical and medical supply support for military healthcare programs globally.
AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, serves as a critical vendor for federal medical procurement, particularly supporting Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The company's extensive portfolio includes brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains. This specific delivery order for HUMIRA, a biologic immunosuppressant commonly used to treat rheumatologic and inflammatory conditions, reflects the company's role in supplying specialty pharmaceuticals essential to military and veteran healthcare operations.
Quick answers
Who was awarded contract SPE2DR26FB4PD?
SPE2DR26FB4PD was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on November 13, 2025.
How much is contract SPE2DR26FB4PD worth?
The government has obligated $32,036 on SPE2DR26FB4PD.
Is contract SPE2DR26FB4PD an order under another contract?
Yes. SPE2DR26FB4PD is a delivery order under SPE2DR25D2208, an indefinite delivery contract.
Was contract SPE2DR26FB4PD competed?
The extent of competition for SPE2DR26FB4PD was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award